SPATA20

Across TCGA pan-cancer cohorts, SPATA20 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPATA20 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SPATA20 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA20 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, PRAD, and UCEC are the cancer types where SPATA20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	0.003	0.630	<.001	15	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.957	0.628	.033	4	view →
SKCM	OS	Median	III,IV	0.216	0.721	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPATA20–STAD (OS)

Open the STAD breakdown →